Clik here to view.
MediMergent and FDA team up to tackle medication adherence
Healthcare data analytics company, MediMergent, and the FDA’s Center for Drug Evaluation and Research reportedly gathered stakeholders from biopharma companies, pharmacies, health plans and regulatory...
View ArticleClik here to view.
In reversal, FDA accepts Alkermes’ depression drug for review
In an about-face, the FDA reportedly agreed to review a new drug application for Alkermes‘ (NSDQ:ALKS) depression drug just weeks after the agency said it would only do so if the company conducted...
View ArticleClik here to view.
Johnson & Johnson’s global pharma sales up 19% in Q1
Johnson & Johnson (NYSE:JNJ) today reported first-quarter sales and earnings results, topping analysts’ expectations on Wall Street. The company’s pharmaceutical business delivered “robust growth,”...
View ArticleClik here to view.
Novocure touts top-line data from Ph2 mesothelioma trial
Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for...
View ArticleClik here to view.
Valeritas inks distro deal in Australia, New Zealand for V-Go insulin...
Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia...
View ArticleClik here to view.
AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug
Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease....
View ArticleClik here to view.
Glooko names digital health veteran as CEO | Personnel Moves – April 17, 2018
Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of...
View ArticleClik here to view.
Report: Amazon abandons drug distribution and supply plans
Amazon‘s (NSDQ:AMZN) Business division has dropped plans to sell and distribute pharmaceutical products to hospitals, according to a new report from CNBC. The shift comes due to the online...
View ArticleClik here to view.
Senators urge HHS to seek lower price for naloxone
U.S. Sens. Debbie Stabenow (D-MI) and Gary Peters (D-MI) penned a letter to the Dept. of Health and Human Services, urging the agency to demand that manufacturers lower the price of the opioid overdose...
View ArticleClik here to view.
Valeritas taps Glooko’s data management platform for next-gen insulin...
According to a newly-inked deal between the two companies, Glooko plans to provide its diabetes data management platform to Valeritas (NSDQ:VLRX) for use with the medtech company’s next-gen V-Go...
View ArticleClik here to view.
Sollis lands $50m for long-acting pain-relief drug
Sollis Therapeutics closed a $50 million round to support a pivotal trial of its non-opioid pain-reliever, according to Ohio-based translator NeuroTechnology Innovations Translator. Deerfield...
View ArticleClik here to view.
Curetis launches diagnostic cartridge for urinary tract infection
Curetis said today that it won CE-IVD marking for its Unyvero cartridge designed to diagnose severe urinary tract infections. The cartridge covers 103 diagnostic targets and can detect 88 pathogens,...
View ArticleClik here to view.
FDA approves IDE trial for Urotronic’s drug-coated balloon
Minneapolis-based Urotronic said this week that the FDA approved an investigational device exemption trial for its Optilume drug-coated balloon catheter, which is designed to treat urethral strictures...
View ArticleClik here to view.
Fresenius abandons $4.3B Akorn merger, citing data integrity probe
Fresenius (ETR:FRE) is walking away from a $4.3 billion merger with U.S. generic drugmaker, Akorn Inc. (NSDQ:AKRX), citing an investigation that found material breaches of FDA data integrity...
View ArticleClik here to view.
FDA approves Medtronic’s drug-coated balloon to treat long superficial...
The FDA approved Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon to treat long superficial femoral artery lesions up to 360mm in patients with peripheral artery disease, the medtech giant...
View ArticleClik here to view.
Orion inks $200m deal to sell diagnostics unit
Orion said today that it plans to sell its Orion Diagnostica division to an investment fund managed by Axcel Management for $200 million. The Finland-based company said its diagnostic unit operates...
View ArticleClik here to view.
Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement
Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from...
View ArticleClik here to view.
Novocure misses sales, EPS estimates in Q1
Shares in Novocure (NSDQ:NVCR) fell today after the medical device maker missed expectations on Wall Street with its first-quarter results. The St. Helier, N.J.-based company posted a net loss of...
View ArticleClik here to view.
Baxter beats The Street with Q1 results
Shares in Baxter (NYSE:BAX) rose today in pre-market activity after the medical device maker beat expectations on Wall Street with its first-quarter results. The Deerfield, Ill.-based company posted...
View ArticleClik here to view.
Abbott pulls Xience Alpine drug-eluting stent from Indian market
Abbott (NYSE:ABT) reportedly stopped selling its Xience Alpine drug-eluting coronary stent in India this week in response to price caps set by the National Pharmaceutical Pricing Authority. A...
View Article